{"product_id":"ghsi-vrio-analysis","title":"Guardion Health Sciences, Inc. (GHSI): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eUnlocking the secrets to Guardion Health Sciences, Inc. (GHSI)'s market staying power starts here: this concise VRIO analysis cuts straight to the chase, revealing precisely which of their assets are truly Valuable, Rare, Inimitable, and Organized for lasting competitive advantage. Don't just guess their strategy - read the distilled verdict below to see if Guardion Health Sciences, Inc. (GHSI) is built to win.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eGuardion Health Sciences, Inc. (GHSI) - VRIO Analysis: 1. Post-Sale Net Cash Position\n\u003c\/h2\u003e\n\u003cp\u003eYou’re looking at the final chapter for Guardion Health Sciences, Inc., where the primary asset is the cash left over after selling the main business driver. The immediate takeaway is that the company’s value now rests almost entirely on its ability to execute the planned wind-down and distribute the remaining capital to you, the shareholder.\u003c\/p\u003e\n\n\u003cp\u003eThe core of this position stems from the sale of the Viactiv brand and business to Doctor's Best Inc. for $17.2 million in cash, which was completed around May 2024. This transaction provided the capital base for the mandated shareholder payout, which was declared as a $3.25 per share cash distribution, expected to be paid on or before December 27, 2024. That distribution amount was based on the cash position after the sale and before final administrative costs are settled.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue: Immediate Capital Base\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe value here is straightforward: it’s the immediate capital available to cover final liabilities and execute the shareholder distributions. This isn't about future earnings; it's about realizing the final value from the asset sale. The company filed its Certificate of Dissolution on October 30, 2024, confirming this focus on asset realization.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity: Size Relative to Market Cap\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe size of this final cash pool, relative to the market capitalization just before the final distribution was announced in late 2024, was notable. One report suggested the $3.25 per share distribution represented approximately 25% of the market cap at that time. For a company entering full dissolution, having a clear, large, per-share cash value is rare; most liquidations are messy and uncertain.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability: A Result of a Unique Past Event\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo competitor can imitate this specific cash balance because it is the direct, non-replicable outcome of the $17.2 million Viactiv sale and the prior approval of the Plan of Liquidation and Dissolution by stockholders on May 31, 2024. It’s a historical artifact, not a repeatable strategy.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization: The Wind-Down Structure\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eGuardion Health Sciences, Inc. is organized specifically to exploit this cash position through a controlled wind-down. Mark Goldstone was appointed Interim President and CEO effective October 18, 2024, to oversee this process. The organization's structure is now purely administrative, focused on settling suits and discharging liabilities over a mandated period, which is the only way to realize the final value.\u003c\/p\u003e\n\n\u003cp\u003eHere’s the quick math on the key liquidation figures:\u003c\/p\u003e\n\u003ctable border=\"1\"\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eMetric\u003c\/td\u003e\n    \u003ctd\u003eValue\/Amount\u003c\/td\u003e\n    \u003ctd\u003eDate\/Context\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eViactiv Sale Price\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e$17.2 million\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eSale to Doctor's Best Inc.\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eDeclared Cash Distribution\u003c\/td\u003e\n    \u003ctd\u003e\n\u003cstrong\u003e$3.25\u003c\/strong\u003e per share\u003c\/td\u003e\n    \u003ctd\u003eRecord Date: October 30, 2024\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eExpected Distribution Payment\u003c\/td\u003e\n    \u003ctd\u003eOn or before \u003cstrong\u003eDecember 27, 2024\u003c\/strong\u003e\n\u003c\/td\u003e\n    \u003ctd\u003eFinal Payout Timeline\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eStockholders Approved Liquidation\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003eMay 31, 2024\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eDate of Shareholder Vote\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eWhat this estimate hides is the final liability settlement amount, which will reduce the final net cash available after all wind-down costs are paid. If onboarding takes 14+ days, churn risk rises - though here, if the final legal settlement takes longer than anticipated, the final distribution amount will shrink.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage: Temporary\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe advantage is strictly \u003cstrong\u003eTemporary\u003c\/strong\u003e. It exists only until the cash is fully distributed and all legal obligations are met. Once the final liquidating dividend is paid, the advantage - the cash pool - vanishes. It’s a one-time event, not a sustained edge.\u003c\/p\u003e\n\u003cp\u003eFinance: draft final liability accrual schedule against the remaining cash balance by next Tuesday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eGuardion Health Sciences, Inc. (GHSI) - VRIO Analysis: 2. Approved Plan of Liquidation and Dissolution\n\u003c\/h2\u003e\n\n\u003cp\u003e\n\u003c\/p\u003e\u003ch3\u003eValue\u003c\/h3\u003e\n\n\u003cp\u003e\nThe Plan of Liquidation and Dissolution establishes a pathway for asset distribution following the sale of the primary revenue driver, which accounted for approximately 97% of total revenue in 2023 and Q1 2024.\n\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eViactiv Brand Sale Proceeds\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$17.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnticipated Liquidating Dividend Per Share\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$3.25\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStock Price as of October 30, 2024\u003c\/td\u003e\n\u003ctd\u003eAround \u003cstrong\u003e$2.50\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePotential Premium on Distribution (as of 10\/30\/2024)\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e30%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\nThe structure is designed to distribute remaining assets to stockholders of record as of the Effective Date.\n\u003c\/p\u003e\n\n\u003cp\u003e\n\u003c\/p\u003e\u003ch3\u003eRarity\u003c\/h3\u003e\n\n\u003cp\u003e\nThe formalization of the dissolution follows the sale of the main asset and the subsequent stockholder vote.\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eStockholders approved the Plan of Liquidation and Dissolution on \u003cstrong\u003eMay 31, 2024\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe Company filed the Certificate of Dissolution with the Secretary of State of the State of Delaware, effective \u003cstrong\u003eOctober 30, 2024\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\n\u003c\/p\u003e\u003ch3\u003eImitability\u003c\/h3\u003e\n\n\u003cp\u003e\nThe specific terms and approvals are unique to Guardion Health Sciences, but the concept of a dissolution plan following an asset sale is not. The Common Stock par value is \u003cstrong\u003e$0.001\u003c\/strong\u003e per share.\n\u003c\/p\u003e\n\n\u003cp\u003e\n\u003c\/p\u003e\u003ch3\u003eOrganization\u003c\/h3\u003e\n\n\u003cp\u003e\nThe Board and management are organized around the plan, evidenced by the formal filing and the cessation of regular business activities.\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe Certificate of Dissolution became effective on \u003cstrong\u003eOctober 30, 2024\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eUnder the General Corporation Law of the State of Delaware (DGCL), Guardion will continue for a term of \u003cstrong\u003ethree years\u003c\/strong\u003e following the Effective Date for winding down purposes.\u003c\/li\u003e\n\u003cli\u003eAs of \u003cstrong\u003eOctober 30, 2024\u003c\/strong\u003e, record holders ceased to have rights in the Common Stock, except the right to receive distributions.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\n\u003c\/p\u003e\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\n\u003cp\u003e\nThe advantage is temporary, tied to the period before the final distribution. The company announced a declaration of a cash distribution expected to be paid by \u003cstrong\u003eDecember 27, 2024\u003c\/strong\u003e.\n\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eGuardion Health Sciences, Inc. (GHSI) - VRIO Analysis: 3. Retained Intellectual Property Rights (VectorVision Segment)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Offers a potential, albeit small, secondary source of cash flow if these rights from the former medical device business can be successfully monetized or sold off. The strategic shift in December 2021 aimed to exploit this IP as an additional revenue stream at nominal cost, following the wind-down of operations targeted for completion by approximately March 31, 2022.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e IP from a wound-down segment is not common; most companies sell it with the business line. The decision to retain and exploit the IP separately is a deviation from the norm for the segment that was being wound down.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e The specific patents or trade secrets are difficult to copy, but their value is unproven in this context, especially post-operational wind-down and subsequent corporate dissolution effective October 30, 2024.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The organization was evaluating opportunities to monetize this IP through licensing and distribution arrangements, showing intent to exploit it before final closure.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. It depends entirely on a successful, future monetization event, which is complicated by the subsequent Plan of Liquidation and Dissolution.\u003c\/p\u003e\n\u003cp\u003eThe financial context surrounding the VectorVision segment's closure and the subsequent corporate actions is summarized below:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eAmount\/Date\u003c\/td\u003e\n\u003ctd\u003eContext\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnticipated Annual Operating Cost Reduction\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$300,000+\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eResulting from winding down VectorVision business operations.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVectorVision Operations Wind-Down Target Date\u003c\/td\u003e\n\u003ctd\u003eMarch 31, 2022\u003c\/td\u003e\n\u003ctd\u003eOriginal target date for completing the cessation of business operations.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eViactiv Sale Gross Cash Consideration\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$17,200,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSale price for the business line that absorbed most of the company's focus\/revenue.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eViactiv Sale Net Proceeds Received\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$16,250,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCash received at closing from the Viactiv sale.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eViactiv Sale Escrow Amount\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$225,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAmount held in escrow from the Viactiv sale.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCorporate Dissolution Effective Date\u003c\/td\u003e\n\u003ctd\u003eOctober 30, 2024\u003c\/td\u003e\n\u003ctd\u003eDate the certificate of dissolution became effective.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe organization's intent regarding the IP exploitation prior to dissolution included:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eExploring both domestic and international business opportunities for the IP.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eFocusing on arrangements such as licensing and distribution for economic exploitation of the VectorVision patents.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eAnticipating the potential for the VectorVision intellectual property rights to serve as an additional revenue stream.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eThe company expected to pay a liquidating dividend to stockholders totaling approximately \u003cstrong\u003e$3.25 per share\u003c\/strong\u003e of Common Stock.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eGuardion Health Sciences, Inc. (GHSI) - VRIO Analysis: 4. Expert Legal Counsel for Corporate Wind-Down\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Minimizes legal risk and ensures compliance during the complex process of settling suits and finalizing regulatory requirements, protecting the remaining cash.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Access to top-tier law firms like Sheppard Mullin for a complex dissolution is a specialized, high-value resource.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Competitors can hire similar firms, but the relationship and institutional knowledge of Guardion Health Sciences’ specific situation are not easily copied.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The company demonstrated organization by utilizing this counsel for the Viactiv sale and the subsequent dissolution filings.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained, for the duration of the wind-down. This expertise is crucial until the final filing.\u003c\/p\u003e\n\u003cp\u003eThe engagement of expert legal counsel was integral to executing the strategic shift following the sale of the Viactiv business, which generated $17.2 million in gross cash consideration. The legal framework guided the transition from active operations to a wind-down status, aiming to distribute accumulated cash to stockholders.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eLegal\/Financial Event\u003c\/th\u003e\n\u003cth\u003eDate\/Amount\u003c\/th\u003e\n\u003cth\u003eReference\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eViactiv Gross Sale Proceeds\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$17.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Cash Proceeds at Closing\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$16.25 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAmount Held in Escrow\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$225,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStockholder Approval of Liquidation Plan\u003c\/td\u003e\n\u003ctd\u003eMay 31, 2024\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCertificate of Dissolution Filed\u003c\/td\u003e\n\u003ctd\u003eOctober 30, 2024\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStock Transfer Books Closed\u003c\/td\u003e\n\u003ctd\u003eOctober 30, 2024\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExpected Liquidating Dividend Per Share\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$3.25\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDuration of Wind-Down Operations\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eThree years\u003c\/strong\u003e post-October 30, 2024\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe legal counsel's role encompassed navigating the regulatory requirements for the dissolution process, which is projected to last for a period of up to \u003cstrong\u003ethree years\u003c\/strong\u003e following the filing of the certificate of dissolution.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eRepresentation secured for the sale of the Viactiv business to Doctor's Best Inc.\u003c\/li\u003e\n\u003cli\u003eGuidance provided for the stockholder vote on the Plan of Liquidation and Dissolution, approved on \u003cstrong\u003eMay 31, 2024\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eFiling of the Certificate of Dissolution with the Delaware Secretary of State, effective \u003cstrong\u003eOctober 30, 2024\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eActions taken to settle suits, discharge liabilities, and distribute remaining assets over the wind-down period.\u003c\/li\u003e\n\u003cli\u003eFacilitation of the declaration of a cash distribution of \u003cstrong\u003e$3.25 per share\u003c\/strong\u003e of Common Stock to stockholders of record as of \u003cstrong\u003eOctober 30, 2024\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eGuardion Health Sciences, Inc. (GHSI) - VRIO Analysis: 5. Established Corporate Compliance and Reporting History\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Successful execution of the Plan of Liquidation and Dissolution, including the filing of the Certificate of Dissolution effective on \u003cstrong\u003eOctober 30, 2024\u003c\/strong\u003e, avoided potential penalties associated with non-compliance during the wind-down process, protecting the declared cash distributions of \u003cstrong\u003e\\$3.25\u003c\/strong\u003e per share (record date \u003cstrong\u003eOctober 30, 2024\u003c\/strong\u003e) and the prior dividend of \u003cstrong\u003e\\$5.00\u003c\/strong\u003e per share (record date \u003cstrong\u003eSeptember 9, 2024\u003c\/strong\u003e).\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e The company secured relief from the SEC to indefinitely suspend reporting obligations under the Act, following the Form 25 filing on \u003cstrong\u003eOctober 11, 2024\u003c\/strong\u003e, for Nasdaq delisting.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e The established record includes the stockholder approval of the Plan on \u003cstrong\u003eMay 31, 2024\u003c\/strong\u003e, and the subsequent completion of the Viactiv brand sale for \u003cstrong\u003e\\$17.2 million\u003c\/strong\u003e gross cash.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Management's active filing of required documents, such as the Certificate of Dissolution on \u003cstrong\u003eOctober 30, 2024\u003c\/strong\u003e, demonstrates organizational capacity to finalize statutory requirements.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary, contingent upon the acceptance of final dissolution paperwork, which follows the initial filing on \u003cstrong\u003eOctober 30, 2024\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eKey compliance and financial milestones related to the dissolution process:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eEvent\u003c\/td\u003e\n\u003ctd\u003eDate\/Amount\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eStockholder Approval of Liquidation Plan\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eMay 31, 2024\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eViactiv Brand Sale Net Proceeds\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$16.25 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInitial Cash Dividend Declared\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e\\$5.00\u003c\/strong\u003e per share\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCertificate of Dissolution Effective Date\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eOctober 30, 2024\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinal Cash Distribution Declared\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e\\$3.25\u003c\/strong\u003e per share\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExpected Final Distribution Payment Date\u003c\/td\u003e\n\u003ctd\u003eOn or before \u003cstrong\u003eDecember 27, 2024\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eCompliance actions taken by the management team:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eFiling of Form 25 with the SEC to remove common stock from Nasdaq listing on or about \u003cstrong\u003eOctober 11, 2024\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eNotification to Nasdaq of intent to delist, with expected suspension of trading on \u003cstrong\u003eOctober 14, 2024\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eFiling of Certificate of Dissolution with Delaware Secretary of State effective \u003cstrong\u003eOctober 30, 2024\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eSecured SEC approval to indefinitely suspend reporting obligations under the Act via Form 15 filing.\u003c\/li\u003e\n\u003cli\u003eCompany continued for a term of \u003cstrong\u003ethree years\u003c\/strong\u003e following the Effective Date for winding down purposes.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eGuardion Health Sciences, Inc. (GHSI) - VRIO Analysis: 6. Shareholder Communication Infrastructure\n\u003c\/h2\u003e\n\u003cp\u003e\nThe infrastructure's value is tied directly to the execution of distributions following the Plan of Liquidation and Dissolution approved on \u003cstrong\u003eMay 31, 2024\u003c\/strong\u003e.\n\u003c\/p\u003e\n\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003e\nEnsures that the remaining shareholders receive timely, accurate information regarding the \u003cstrong\u003e\\$3.25\u003c\/strong\u003e and \u003cstrong\u003e\\$5.00\u003c\/strong\u003e distributions, maintaining fiduciary trust during winding down.\n\u003c\/p\u003e\n\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003e\nA dedicated, recent history of communicating large cash returns is a positive signal for the remaining holders.\n\u003c\/p\u003e\n\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003e\nThe process itself is standard, but the trust built through recent, large payouts is harder to replicate.\n\u003c\/p\u003e\n\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003e\nThe company has a clear history of press releases for dividend declarations and payments, evidenced by the following timeline of key events:\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eStockholder approval of Plan of Liquidation and Dissolution: \u003cstrong\u003eMay 31, 2024\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eDeclaration of \u003cstrong\u003e\\$5.00\u003c\/strong\u003e per share cash dividend (Record Date: \u003cstrong\u003eSeptember 9, 2024\u003c\/strong\u003e; Payment Date: \u003cstrong\u003eSeptember 23, 2024\u003c\/strong\u003e).\u003c\/li\u003e\n\u003cli\u003eFiling of Certificate of Dissolution: \u003cstrong\u003eOctober 30, 2024\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eDeclaration of \u003cstrong\u003e\\$3.25\u003c\/strong\u003e per share cash distribution (Record Date: \u003cstrong\u003eOctober 30, 2024\u003c\/strong\u003e; Expected Payment by \u003cstrong\u003eDecember 27, 2024\u003c\/strong\u003e).\u003c\/li\u003e\n\u003cli\u003eCompany continuation for winding down: \u003cstrong\u003eThree years\u003c\/strong\u003e following \u003cstrong\u003eOctober 30, 2024\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\nKey distribution metrics and related share data:\n\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistribution Event\u003c\/td\u003e\n\u003ctd\u003ePer Share Amount\u003c\/td\u003e\n\u003ctd\u003eRecord Date\u003c\/td\u003e\n\u003ctd\u003eShares Outstanding (Approx.)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Dividend\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$5.00\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eSeptember 9, 2024\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eData not specified for this date\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLiquidating Distribution\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$3.25\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eOctober 30, 2024\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e1,349,956\u003c\/strong\u003e (as of 09\/30\/2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003e\nTemporary. It is most valuable until the final distribution is made. The Market Cap was reported at \u003cstrong\u003e\\$4.39M\u003c\/strong\u003e with a Float of \u003cstrong\u003e1.33M\u003c\/strong\u003e near the dissolution filings.\n\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eGuardion Health Sciences, Inc. (GHSI) - VRIO Analysis: 7. Interim Executive Leadership Focused on Liquidation\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue: Provides clear, singular focus on asset disposition and liability settlement, preventing mission creep back into operations.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe appointment of leadership specifically for dissolution supports the realization of cash distributions, such as the anticipated liquidating dividend of approximately \u003cstrong\u003e$3.25 per share\u003c\/strong\u003e to stockholders of record on \u003cstrong\u003eOctober 30, 2024\u003c\/strong\u003e. The company filed its Certificate of Dissolution on \u003cstrong\u003eOctober 30, 2024\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity: Having a specifically appointed Interim President and CEO for dissolution is a clear structural signal.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe appointment of an executive solely for wind-down is rare outside of formal bankruptcy, signaling a definitive end to operational pursuits. The company's cash position as of \u003cstrong\u003eJune 30, 2024\u003c\/strong\u003e was \u003cstrong\u003e$14,822,826\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability: The specific individual appointed, Mark Goldstone, is unique to Guardion Health Sciences.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eMark Goldstone was appointed Interim President and CEO effective \u003cstrong\u003eOctober 18, 2024\u003c\/strong\u003e, replacing Jan Hall who departed effective \u003cstrong\u003eOctober 17, 2024\u003c\/strong\u003e. Mr. Goldstone's compensation is reported at \u003cstrong\u003e$7,500 monthly\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization: The appointment itself shows the Board is organized for the wind-down phase.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe Board's organization is evidenced by the sequence of events following stockholder approval of the Plan of Liquidation and Dissolution on \u003cstrong\u003eMay 31, 2024\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eStockholders approved the Plan of Liquidation and Dissolution on \u003cstrong\u003eMay 31, 2024\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eSale of Viactiv brand generated \u003cstrong\u003e$17.2 million\u003c\/strong\u003e in cash.\u003c\/li\u003e\n\u003cli\u003eCertificate of Dissolution filed on \u003cstrong\u003eOctober 30, 2024\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eStock transfer books closed on \u003cstrong\u003eOctober 30, 2024\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eExpected liquidating dividend payment by \u003cstrong\u003eDecember 27, 2024\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage: Temporary. This leadership structure is designed to be temporary by definition.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe structure is inherently temporary, designed to conclude within the statutory period for dissolution under Delaware law, which allows the company to continue for up to \u003cstrong\u003ethree years\u003c\/strong\u003e solely for wind-down activities.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMilestone\/Metric\u003c\/th\u003e\n\u003cth\u003eDate\/Amount\u003c\/th\u003e\n\u003cth\u003eSource Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eInterim CEO Appointment Date\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eOctober 18, 2024\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eEffective date for Mark Goldstone\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCertificate of Dissolution Filing\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eOctober 30, 2024\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eEffective date of dissolution\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRecord Date for Distribution\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eOctober 30, 2024\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eDate for stockholders to receive distribution right\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExpected Distribution Payment Date\u003c\/td\u003e\n\u003ctd\u003eOn or before \u003cstrong\u003eDecember 27, 2024\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eExpected payment timeline\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnticipated Liquidating Distribution\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$3.25 per share\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eTotal expected cash distribution\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eViactiv Sale Proceeds\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$17.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCash generated from asset disposition\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eShares Outstanding (Q2 End)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1,284,156\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eShares outstanding as of \u003cstrong\u003eJune 30, 2024\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eGuardion Health Sciences, Inc. (GHSI) - VRIO Analysis: 8. Historical Product Valuation Data (Viactiv)\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The documented \u003cstrong\u003e$17.2 million\u003c\/strong\u003e gross cash sale price provides a concrete, recent benchmark for valuing the company’s former core asset, which informs the current residual value proposition. The net cash proceeds received at closing were \u003cstrong\u003e$16.25 million\u003c\/strong\u003e, with an additional \u003cstrong\u003e$225,000\u003c\/strong\u003e retained in a third-party escrow account as of the May 31, 2024, closing date.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e A recent, arm's-length sale price for the primary asset is a very strong, rare data point for a shell company. The Viactiv business accounted for approximately \u003cstrong\u003e97.2%\u003c\/strong\u003e of total revenue for the year ended December 31, 2023.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e The fact of the sale price is immutable, but the application of that data is what matters. The transaction resulted in a reported gain on sale of discontinued operations of \u003cstrong\u003e$12,742,385\u003c\/strong\u003e for the six months ended June 30, 2024.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The company has clearly documented this transaction in its public filings. Stockholders approved the sale and the subsequent Plan of Liquidation and Dissolution at a Special Meeting on May 31, 2024.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. This historical transaction value will underpin any final valuation discussions or residual claims. Subsequent to the sale, the company announced a cash distribution of \u003cstrong\u003e$3.25 per share\u003c\/strong\u003e of common stock to stockholders of record as of October 30, 2024.\u003c\/p\u003e\n\n\u003cp\u003eThe following table summarizes key financial figures related to the Viactiv asset and the subsequent corporate actions:\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eAmount\u003c\/th\u003e\n\u003cth\u003eDate\/Period Reference\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Cash Sale Price (Viactiv)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$17,200,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eMay 31, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Cash Proceeds at Closing\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$16,250,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eMay 31, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAmount Held in Escrow\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$225,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eMay 31, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGain on Sale of Discontinued Operations\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$12,742,385\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSix Months Ended June 30, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eViactiv Net Revenues\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$11,907,867\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eYear Ended December 31, 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eViactiv Revenue as % of Total Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e97.2%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eYear Ended December 31, 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Distribution Per Share\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3.25\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eRecord Date October 30, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eKey financial details surrounding the Viactiv business and the post-sale environment include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eViactiv generated net revenues of \u003cstrong\u003e$11,907,867\u003c\/strong\u003e for the year ended December 31, 2023, an increase of \u003cstrong\u003e11.9%\u003c\/strong\u003e from \u003cstrong\u003e$10,640,119\u003c\/strong\u003e in 2022.\u003c\/li\u003e\n\u003cli\u003eGross profit for the year ended December 31, 2023, was \u003cstrong\u003e$5,394,517\u003c\/strong\u003e, an increase of \u003cstrong\u003e19.3%\u003c\/strong\u003e over 2022.\u003c\/li\u003e\n\u003cli\u003eThe company's cash position was \u003cstrong\u003e$14.8 million\u003c\/strong\u003e as of June 30, 2024, following the sale.\u003c\/li\u003e\n\u003cli\u003eThe company redeemed Series A Warrants for \u003cstrong\u003e$5.6 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eLoss from continuing operations for the six months ended June 30, 2024, was \u003cstrong\u003e$(6,727,289)\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eGuardion Health Sciences, Inc. (GHSI) - VRIO Analysis: 9. Low Current Operational Overhead\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Since the main revenue driver is gone and operations are minimal, the burn rate is drastically reduced, preserving cash for the final distributions.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e A company that has successfully shed its primary operational costs while retaining cash is in a unique, low-overhead state.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Competitors can't easily achieve this without selling their own core business.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The move to Houston and the sale of Viactiv demonstrate a commitment to cost reduction.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. Overhead will eventually rise slightly to cover the three-year wind-down period, but it remains low.\u003c\/p\u003e\n\u003cp\u003eThe reduction in operational scale is evidenced by the comparison of total operating expenses for the six-month periods ending June 30, 2023, and June 30, 2024, as detailed below:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eSix Months Ended June 30, 2023\u003c\/td\u003e\n\u003ctd\u003eSix Months Ended June 30, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Operating Expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3,150,315\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2,855,944\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOcular Products Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$173,874\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$154,037\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe company's minimal operations post-sale are reflected in the low revenue from continuing ocular products, which was \u003cstrong\u003e$72,918\u003c\/strong\u003e for the three months ended June 30, 2024. The headcount is reported at \u003cstrong\u003e9\u003c\/strong\u003e employees.\u003c\/p\u003e\n\u003cp\u003eFinance: draft final cash reconciliation statement by next Tuesday.\u003c\/p\u003e\n\u003cp\u003eKey financial and liquidation milestones supporting the low-overhead state include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eGross cash consideration for the Viactiv sale to Doctor's Best Inc. was \u003cstrong\u003e$17,200,000\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eNet cash proceeds received at closing from the Viactiv sale amounted to \u003cstrong\u003e$16,250,000\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eAn additional \u003cstrong\u003e$225,000\u003c\/strong\u003e from the sale was placed in a third-party escrow account.\u003c\/li\u003e\n\u003cli\u003eAs of June 30, 2024, the Company reported \u003cstrong\u003e$14,822,826\u003c\/strong\u003e of cash on hand.\u003c\/li\u003e\n\u003cli\u003eThe Board declared a cash distribution of \u003cstrong\u003e$3.25 per share\u003c\/strong\u003e of common stock to stockholders of record as of October 30, 2024.\u003c\/li\u003e\n\u003cli\u003eA prior cash dividend of \u003cstrong\u003e$5.00 per share\u003c\/strong\u003e of common stock was declared for stockholders of record as of September 9, 2024.\u003c\/li\u003e\n\u003cli\u003eThe approved Plan of Liquidation and Dissolution mandates the company continue operations for \u003cstrong\u003ethree years\u003c\/strong\u003e solely for wind-down purposes.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516172329109,"sku":"ghsi-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/ghsi-vrio-analysis.png?v=1740179922","url":"https:\/\/dcf-model.com\/pt\/products\/ghsi-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}